---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-220722"
form_type: "8-K"
ticker: "QNCX"
cik: "0001662774"
company_name: "Quince Therapeutics, Inc."
filed_at: "2025-09-26T23:59:59+00:00"
generated_at: "2026-05-17T05:34:12.624339+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Quince amends EIB credit facility; min cash balance reduced to EUR 5M for Q1 2026

## Summary
- Minimum cash balance reduced from EUR 14.65M to EUR 5M for Jan-Mar 2026 period.
- 1% of 9% deferred interest converted to fixed rate, payable March 31, 2026.
- Amendment dated September 25, 2025 under EIB Facility originally July 24, 2020.

## SEC filing metadata
- accession: 0001193125-25-220722
- form_type: 8-K
- ticker: QNCX
- cik: 0001662774
- company_name: Quince Therapeutics, Inc.
- filed_at: 2025-09-26T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1662774/000119312525220722/0001193125-25-220722-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1662774/000119312525220722/d911581d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-220722
- JSON: https://secwatch.observer/filing/0001193125-25-220722.json
- Plain text: https://secwatch.observer/filing/0001193125-25-220722.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.